Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.

@article{Sulkes2010NovelMA,
  title={Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.},
  author={Aar{\'o}n Sulkes},
  journal={The Israel Medical Association journal : IMAJ},
  year={2010},
  volume={12 10},
  pages={628-32}
}
  • Aarón Sulkes
  • Published 2010 in The Israel Medical Association journal : IMAJ
The introduction of novel targeted therapies into the clinic in recent years has had a considerable impact on the management of several neoplastic diseases--such as gastrointestinal stromal tumors, hepatocellular carcinomas and renal cell carcinomas--considered until recently refractory to systemic therapies. We describe here two such novel biological agents, sunitinib and sorafenib, as a paradigm of the successful clinical application of new concepts. Sunitinib and sorafenib are small molecule… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…